News About: Pharm. Industry
Yuhan Corporation acquires ‘Sovaldi’ & ‘Harvoni’ license worth of KRW 120 billion a year
In the official notice on the 5th, Yuhan Corporation announced it signed an exclusive sales agreement of ‘Sovaldi’ and ‘Harvoni,’ hepatitis C treatments, in Korea with U.S. Gilead.
Gilead’s ‘Sovaldi’ and ‘Harvoni’ sa...
Chong Kun Dang runs new global drug for treatment of dyslipidemia
As new clinical trial results of dyslipidemia treatment were recently revealed in the U.S., ‘CKD-519’ being developed by Chong Kun Dang has raised expectations.
CKD-519, a new dyslipidemia drug with a new mechanism t...
Handok completes construction of plaster factory, firming foundation to become total healthcare company
After getting ‘Ketotop,’ an attachable arthritis treatment, by acquiring the Pacific Pharmaceuticals’ pharmaceutical business in 2014, Handok has once raised competitiveness in the penetration product field by constru...
CorePharm Bio wins patent dispute against ‘Astellas, a multinational pharma
CorePharm Bio(CEO Jung-Tae Kim) announced that the Patent Court ruled the company’s A-Care Tab(generic name: solifenacin fumarate) does not infringe the Astellas’ solifenacin substance patent on the 30th of June.
The...
Increase of approvals for OTC drugs
It was observed approvals for OTC medicines, which have been slow lately, are increasing this year.
According to the Ministry of Food and Drug Safety(MFDS), there were 1,016 pharmaceutical products newly approved bet...
Pharmaceutical manufacturers available in food manufacturing using their own medicine manufacturing facilities
As regulations were eased for current pharmaceutical manufacturers to manufacture and process foods using their own pharmaceutical manufacturing facilities, they now are able to expand their business in the food field...
Pfizer’s perseverance towards rare disease treatments
What is people’s recognition about ‘rare disease’? Normally, they think it is a disease that is uncommon, hard to be cured and have a high mortality rate.
They are not totally wrong. A rare disease appears when they ...
Korean biotechnology companies need differentiated strategies
What are essential conditions for Korean biopharmaceutical companies to grow ahead of the Fourth Industrial Revolution?
Global experts chose governmental innovation and executive ability as the condition, stressing d...
Handok completes construction of plaster factory with KRW 30 billion investmentHandok(Chairman Young-Jin Kim) held a ribbon-cutting ceremony for ‘Plaster Manufacturing Factory’ at Eumseong Factory in Chungbuk on the 27th.
Handok secured ‘Ketotop,’ an atta...
|
Manufacturing performance and balance-of-trade surpluses exceeds respective KRW 13 trillion and KRW 3 trillion last year
It was examined that the last year’s manufacturing performance and trade surpluses of cosmetics exceeded KRW 13 trillion and KRW 3 trillion respectively.
The Ministry of Food and Drug Safety(MFDS) announced on the 27...
